减瘤性肾切除术的个体化适应证:哪些标准能定义最佳候选者?
本文通过协作性批判性叙述性文献综述,评估减瘤性肾切除术(CN)最佳候选者的定义标准。CARMENA试验显示单纯靶向治疗相对于CN联合靶向治疗的非劣效性;SURTIME试验报告立即与延迟CN后无进展生存率相似,并提示术前全身治疗可识别CN候选者。作者认为全身治疗应优先于CN,CN适用于不需立即全身治疗的良好风险病例或有症状患者,个体化选择至关重要。
要点
- 随机对照试验显示,需要全身治疗的中危和低危患者接受 upfront CN 无获益,全身治疗应优先于 CN。
- CN 与显著的围手术期死亡风险(0-13%)和重大并发症(3-36%)相关。
- 已提出转移负荷、血液学参数、体能状态、肌肉减少症和基因突变作为 CN eligibility 标准,推荐使用综合模型。
核心结论
- 随机对照试验中,需要全身治疗的中危和低危患者接受 upfront CN 未观察到获益,转移性肾细胞癌患者全身治疗应优先于 CN。
- 这些发现不适用于所有转移性肾癌患者,CN 在不需立即全身治疗的良好病例或有症状患者中仍有作用。
- 个体化患者选择以识别最可能从 CN 获益的患者至关重要,但临床决策应基于综合模型。
- 术前全身治疗是避免不必要 CN 的有前景选择,CN 与重大并发症相关。
研究设计与样本
- 协作性批判性叙述性文献综述,聚焦 CN 肿瘤学结局、围手术期并发症、入选标准、术前全身治疗和手术因素。
主要发现
- 与观察性研究相反,CARMENA 试验证明单纯靶向治疗相对于 CN 联合靶向治疗的非劣效性。
- CN 与显著的围手术期死亡风险(0-13%)和重大并发症(3-36%)相关。
- SURTIME 试验报告立即或延迟 CN 后无进展生存率相似,并提示术前全身治疗可识别 CN 候选者,避免对无应答者的不必要手术且不增加围手术期并发症风险。
- 微创和保留肾单位的 CN 是特定患者中已确立的手术策略。
关键数值与推荐
- 已提出转移负荷、血液学参数、体能状态、肌肉减少症和基因突变作为 CN 入选标准,推荐使用包括局部和全身因素的综合模型。
临床怎么用
- 转移性肾细胞癌患者全身治疗应优先于 CN,CN 适用于不需立即全身治疗的良好病例或有症状患者,临床决策应基于综合模型,风险评分和术前全身治疗反应可用于后续决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The current role of cytoreductive nephrectomy (CN) is controversial. OBJECTIVE: Review of the available evidence about criteria defining CN optimal candidates. EVIDENCE ACQUISITION: Collaborative critical narrative review of the literature focusing on CN oncological outcomes, perioperative morbidity, eligibility criteria, presurgical systemic therapy, and surgical factors. EVIDENCE SYNTHESIS: In contrast to observational studies, the Clinical Trial to Assess the Importance of Nephrectomy (CARMENA) trial demonstrated noninferiority of targeted therapy alone relative to CN with targeted therapy. CN is associated with a significant risk of perioperative mortality (0-13%) and major complications (3-36%). Metastatic burden, haematological parameters, performance status, sarcopenia, and genetic mutations have been proposed as CN eligibility criteria. Comprehensive models including local and systemic factors are recommended. The Immediate Surgery or Surgery after sunitinib Malate In Treating Patients with Kidney Cancer (SURTIME) trial reported similar progression-free rate after immediate or deferred CN, and suggests that presurgical systemic therapy can identify candidates for CN, avoiding unnecessary surgery in nonresponders without increasing the risk of perioperative complications. Minimally invasive and nephron-sparing CNs are established surgical strategies in selected patients. CONCLUSIONS: No benefit of upfront CN is observed for intermediate- and poor-risk patients who require systemic therapy in randomised controlled trials, and systemic therapy deserves priority over CN in patients with metastatic renal cell carcinoma. These findings are not applicable to all patients with metastatic kidney cancer. CN has a role in favourable cases not requiring immediate systemic therapy or in symptomatic patients. Individual patient selection to identify those patients who might profit the most from CN is critical; however, clinical decision making should be based on comprehensive models. Presurgical systemic therapy is a promising option to avoid unnecessary CN, which is associated with major morbidity. PATIENT SUMMARY: Consideration for systemic therapy deserves priority over cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma. In patients eligible for systemic therapy, CN does not offer a survival benefit. The indications for CN should be evaluated on an individual basis. Risk scores and response to presurgical systemic therapy can be used for subsequent decision making.
引用
- Larcher A, Wallis CJD, Bex A, et al. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? Eur Urol Oncol. 2019. PMID: 31109902. doi:10.1016/j.euo.2019.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。